Supplementary table 1 Included publications in the review

|  |  |  |  |
| --- | --- | --- | --- |
| **Author** | **Publication year** | **Title** | Brief c**itation** |
| Neilson LM, Swart ECS, et al. | 2019 | Identifying Outcome Measures for Coronary Artery Disease Value-Based Contracting Using the Delphi Method. | Cardiol Ther. 2019 Mar 1 [Epub ahead of print] |
| Neilson LM, Swart ECS, et al. | 2019 | Identifying Outcome Measures for Type 2 Diabetes Value-Based Contracting Using the Delphi Method. | J Manag Care Spec Pharm. 2019 Mar;25(3):324-331. |
| Capozzi M, De Divitiis C, et al. | 2018 | Funds Reimbursement of High-Cost Drugs in Gastrointestinal Oncology: An Italian Real Practice 1 Year Experience at the National Cancer Institute of Naples. | Front Public Health. 2018 Oct 12;6:291. |
| Palace J., Duddy M., et al. | 2018 | Assessing the long-term effectiveness of interferon-beta and glariramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclrosis risk-sharing scheme | J Neurol Neurosurg Psychiatry. 2019 Mar;90(3):251-260. |
| Kefalas P., Ali O., et al. | 2018 | Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy. | J Mark Access Health Policy. 2018 Aug 20;6(1):1511679. |
| Goncalves F., Santos S., et al | 2018 | Risk-sharing agreements, present and future | Ecancermedicalscience. 2018 Apr 10;12:823. |
| Bouvy J., Sapede C. et al. | 2018 | Managed entry agreements for pharmaceuticals in the context of adaptive pathways in Europe | Front Pharmacol. 2018 Mar 27;9:280. |
| Dunlop W., Staufer A., et al. | 2018 | Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience. | Health Policy. 2018 May;122(5):528-532. |
| Brown JD, Sheer R, et al. | 2018 | Payer and pharmaceutical manufacturer considerations for outcomes-based agreements in the United States | Value Health. 2018 Jan;21(1):33-40. |
| Jorgensen J., Kefalas P. | 2017 | Annuity payments can increase patient access to innovative cell and gene therapies under England's net budget impact test | Journal of market access & health policy, 2017, 5,1355203 |
| Driscoll D, Farnia S, et al. | 2017 | Concise Review: The high cost of high tech medicine: planning ahead for market access | Stem Cells Transl Med. 2017 Aug;6(8):1723-1729. |
| Garrison LP Jr, Carlson JJ, et al. | 2015 | Private sector risk-sharing agreements in the United States: trends, barriers, and prospects. | Am J Manag Care. 2015 Sep;21(9):632-40. |
| Garattini L, Curto A. | 2016 | Performance-based agreements in Italy: 'Trendy outcomes" or mere illusions | Garattini L, Curto A. PharmacoEconomics, 2016, 34(10):967-9 |
| Morel T, Arickx F, et al. | 2013 | Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: A comparative study of managed entry agreements across seven European countries | Morel et al. Orphanet Journal of Rare Diseases, 2013, 8:198 |
| Garrison LP Jr, Towse A, et al. | 2013 | Performance-based risk-sharing arrangements - Good practices for design, implementation, and evaluation: Report of the ISPOR Good Practices for performance-based risk-sharing arrangements task force | Garrison P., et al., Value In Health, 2013, 16: 703 - 719 |
| Walker S, Sculpher M, et al., | 2012 | Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions. | Value Health. 2012 May;15(3):570-9. |
| Lum K, Bhatti T, et al. | 2018 | Diagnosis Confirmation Model: A Value-Based Pricing Model for Inpatient Novel Antibiotics. | J Law Med Ethics. 2018 Jun;46(1\_suppl):66-74. |
| Piatkiewicz TJ, Traulsen JM, et al. | 2018 | Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends. | Pharmacoecon Open. 2018 Jun;2(2):109-123. |
| Barlas S. | 2016 | Health plans and drug companies dip their toes into value-based pricing | P&T. 2016 Jan;41(1):39-53. |
| Navarria A, Drago V, et al. | 2015 | Do the current performance-based schemes in Italy really work? "Success fee": a novel measure for cost-containment of drug expenditure. | Value Health. 2015 Jan;18(1):131-6. |
| Campillo-Artero C, del Llano J, et al. | 2012 | Risk sharing agreements: with orphan drugs? | Farm Hosp. 2012 Nov-Dec;36(6):455-63. |
| Yu JS., chin L., et al. | 2017 | Performance-based risk-sharing agreements for pharmaceutical products in the United States: A systematic review | J Manag Care Spec Pharm. 2017 Oct; 23(10): 1028-1040. |
| Pauwels K, Huys I, et al. | 2017 | Managed entry agreements for oncology drugs: lessons from the European experience to inform the future | Front Pharmaco. 2017 Apr 4;8:171 |
| Klemp M, Fronsdal KB, et al. | 2011 | What principles should govern the use of managed entry agreements? | Inter J Techno Assessment in Health Care. 2011; 27(01):77-83 |
| Dentzer S. | 2018 | Value-based contracting: creating the terms of engagement around high-cost cancer therapies | Am J Manag Care. 2018 Apr; 24(5 Spec No.): SP149-SP150 |
| Darba J, Ascanio M | 2019 | The current performance-linked and risk sharing agreement scene in the Spanish region of Catalonia | Expert Rev Pharmacoecon Outcomes Res. 2019 Mar 6:1-6 |
| Garattini L, Curto A, et al. | 2015 | Italian risk-sharing agreements on drugs: are they worthwhile? | Eur J Health Econ. 2015 Jan; 16(1):1-3 |
| Neumann PJ, Chambers JD, et al. | 2011 | Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement | Health Aff. 2011 Dec; 30(12):2329-37 |
| Garattinni L, Casadei G. | 2011 | Risk sharing agreements: what lessons from Italy? | Int J Technol Assess Health Care. 2011 Apr; 27(2):169-72 |
| van de Vooren K., Curto A., et al | 2015 | Market-access agreements for anti-cancer drugs | [J R Soc Med. 2015 May;108(5):166-70.](https://www.ncbi.nlm.nih.gov/pubmed/25488094) |
| Carlson J., Chen S., Garrison LP. | 2017 | Performance-based risk-sharing arrangements: An updated international review | Pharmacoeconomics. 2017 Oct: 35(10): 1063 - 1072 |